Are you a journalist?

Get to know ALK

If you have any queries please feel free to contact Media Relations at ALK headquarters or one of our global offices.

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.


  • Post date
    ACARIZAX® approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
  • Post date
    ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan
  • Post date
    Grant of share options and performance shares to members of the Board of Management and key employees
  • Post date
    Annual General Meeting in ALK-Abelló A/S held on 15 March 2017
  • Post date
    ALK appoints SVP of R&D for North America and International Markets
  • Post date
    ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe)
  • Post date
    ALK’s ACARIZAX® data results in significant change to the GINA asthma management strategy: Sublingual allergy immunotherapy (SLIT) recommended as a treatment option in patients with house dust mite allergic asthma
  • Post date
    ALK submits registration application for ragweed SLIT-tablet in Europe
  • Post date
    Annual General Meeting in ALK-Abelló A/S on 15 March 2017

Media Relations

Per Plotnikof
Vice President,
Corporate Communications,
Investor Relations and Strategic Planning
Phone: +45 22612525

Jeppe Ilkjær
Media Relations Manager
Corporate Communications
Phone: +45 30502014

Journalists are always welcome to contact ALK’s Media Relations team.
Flemming Pedersen, CFO
Helle Skov, EVP Product Supply
Søren Niegel, EVP Commercial Operations
Henrik Jacobi, EVP Research and Development
Production facilities, Hørsholm
Production facilities, Hørsholm
Production facilities, Hørsholm
ALK HQ, Hørsholm
Last updated: 2017.01.11